sun-dragon
   ABUS Historical Stock Prices »
Video: What is a Stock Split?


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Arbutus Biopharma is a therapeutic solutions company focused on discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus (HBV) infection. Co.'s HBV pipeline consists of multiple drug candidates, with differing and complementary mechanisms of action. The candidates include: RNAi 1.0 (ARB-1467), which is Co.'s main RNA Interference (RNAi) HBV candidate designed to eliminate HBV surface antigen expression in patients chronically infected with HBV; RNAi 2.0 (ARB-1740), Co.'s follow-on RNAi HBV candidate; and Core Protein/ Capsid Assembly Inhibitors (AB-423), which is being developed as oral therapeutics for the treatment of chronic HBV infection. According to our Arbutus Biopharma stock split history records, Arbutus Biopharma has had 1 split.
Arbutus Biopharma stock split history picture
Arbutus Biopharma (ABUS) has 1 split in our Arbutus Biopharma stock split history database. The split for ABUS took place on November 04, 2010. This was a 1 for 5 reverse split, meaning for each 5 shares of ABUS owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 200 share position following the split.

When a company such as Arbutus Biopharma conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share. Looking at the Arbutus Biopharma stock split history from start to finish, an original position size of 1000 shares would have turned into 200 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Arbutus Biopharma shares, starting with a $10,000 purchase of ABUS, presented on a split-history-adjusted basis factoring in the complete Arbutus Biopharma stock split history. Arbutus Biopharma split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 04/28/2008
End date: 04/26/2018
Start price/share: $5.90
End price/share: $5.83
Dividends collected/share: $0.00
Total return: -1.19%
Average Annual Total Return: -0.12%
Starting investment: $10,000.00
Ending investment: $9,880.65
Years: 10.00
Date Ratio
11/04/20101 for 5

More latest
Latest
Latest
Funds Holding Arbutus Biopharma
Arbutus Biopharma Insider Buying